对MAPK抑制剂的专利审查 (2018年至今)
Valentin R Wydra1, Raphael B Ditzinger1, Nico J Seidler1
1Department of Pharmaceutical and Medicinal Chemistry, Eberhard Karls Universit't Tübingen, Tübingen, Germany.
Expert opinion on therapeutic patents
|July 28, 2023
概括
最近的专利揭示了高度选择性的基激活蛋白激酶 (MAPK) 抑制剂,包括p38 MAP激酶,JNK和ERK. 这些进展旨在减少副作用,并可能导致首个批准的MAPK抑制剂药物.
科学领域:
- 生物化学和药理学 生物化学和药理学
- 药物发现和开发 药物发现和开发
背景情况:
- 线原激活蛋白激酶 (MAPK) 在癌症和炎症等各种疾病中至关重要.
- 现有的研究重点是开发选择性的MAPK抑制剂和向蛋白质降解.
研究的目的:
- 从2018年到2023年初审查新专利的MAPK抑制剂.
- 分析这些抑制剂的专利细节,开发时间表和临床试验数据.
主要方法:
- 系统地搜索专利数据库和科学文献.
- 对27项已识别的专利和相关出版物的分析.
- 对专利MAPK抑制剂的临床试验信息的审查.
主要成果:
- 在指定期限内确定了27项新型MAPK抑制剂的专利.
- 具有高选择性的突出抑制剂,包括异形特异性向.
- 观察到MAPK抑制剂的持续临床试验活动.
结论:
- 尽管经过数十年的研究,新的MAPK抑制剂仍在出现.
- 新抑制剂的高级选择性概况有望减少副作用.
- 这些进展为MAPK抑制剂的潜在监管批准铺平了道路.
相关概念视频
MAPK Signaling Cascades
5.7K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.7K
M-Cdk Drives Transition Into Mitosis
5.6K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.6K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Interactions Between Signaling Pathways
6.3K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K


